Stay updated on Comparing Brigimadlin With Doxorubicin in Liposarcoma Clinical Trial
Sign up to get notified when there's something new on the Comparing Brigimadlin With Doxorubicin in Liposarcoma Clinical Trial page.

Latest updates to the Comparing Brigimadlin With Doxorubicin in Liposarcoma Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check9 days agoChange DetectedThe webpage has been updated to include new information about planned maintenance, results reporting dates, and detailed descriptions of treatment protocols for advanced dedifferentiated liposarcoma, including dosages and survival metrics. Notably, the previous mention of a 30-month progression-free survival has been replaced with a 20.6-month figure.SummaryDifference29%
- Check16 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.8%
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check45 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check52 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
Stay in the know with updates to Comparing Brigimadlin With Doxorubicin in Liposarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparing Brigimadlin With Doxorubicin in Liposarcoma Clinical Trial page.